ATE496922T1 - Mglur1-antagonisten als therapeutische wirkstoffe - Google Patents

Mglur1-antagonisten als therapeutische wirkstoffe

Info

Publication number
ATE496922T1
ATE496922T1 AT06848624T AT06848624T ATE496922T1 AT E496922 T1 ATE496922 T1 AT E496922T1 AT 06848624 T AT06848624 T AT 06848624T AT 06848624 T AT06848624 T AT 06848624T AT E496922 T1 ATE496922 T1 AT E496922T1
Authority
AT
Austria
Prior art keywords
antagonists
glutamate receptor
compounds
metabotropic glutamate
therapeutic agents
Prior art date
Application number
AT06848624T
Other languages
English (en)
Inventor
Julius Matasi
Deen Tulshian
Duane Burnett
Wen-Lian Wu
Peter Korakas
Lisa Silverman
Sasikumar Thavalakulamgara
Li Qiang
Martin Domalski
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ATE496922T1 publication Critical patent/ATE496922T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT06848624T 2005-12-13 2006-12-11 Mglur1-antagonisten als therapeutische wirkstoffe ATE496922T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/301,672 US7598259B2 (en) 2004-06-15 2005-12-13 mGluR1 antagonists as therapeutic agents
PCT/US2006/046943 WO2007070393A2 (en) 2005-12-13 2006-12-11 Mglur1 anatgonists as therapeutic agents

Publications (1)

Publication Number Publication Date
ATE496922T1 true ATE496922T1 (de) 2011-02-15

Family

ID=38163430

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06848624T ATE496922T1 (de) 2005-12-13 2006-12-11 Mglur1-antagonisten als therapeutische wirkstoffe

Country Status (8)

Country Link
US (2) US7598259B2 (de)
EP (1) EP1966220B1 (de)
JP (1) JP2009519337A (de)
CN (1) CN101437828A (de)
AT (1) ATE496922T1 (de)
CA (1) CA2633093A1 (de)
DE (1) DE602006019911D1 (de)
WO (1) WO2007070393A2 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20060526A1 (es) * 2004-06-15 2006-07-13 Schering Corp Compuestos triciclicos como antagonistas de mglur1
US7598259B2 (en) * 2004-06-15 2009-10-06 Schering Corporation mGluR1 antagonists as therapeutic agents
WO2006081072A1 (en) * 2005-01-24 2006-08-03 Abbott Laboratories Antagonists of the mglu receptor and uses thereof
EP1931683B1 (de) * 2005-08-19 2011-07-13 Schering Corporation Kondensierte tricyclische mglur1-antagonisten als therapeutische mittel
WO2007038209A2 (en) * 2005-09-23 2007-04-05 Schering Corporation Fused tetracyclic mglur1 antagonists as therapeutic agents
ATE511509T1 (de) * 2006-11-30 2011-06-15 Genentech Inc Azaindolylverbindungen und anwendungsverfahren
GB0713686D0 (en) 2007-07-13 2007-08-22 Addex Pharmaceuticals Sa New compounds 2
AU2013290080A1 (en) * 2012-07-11 2015-01-29 Nimbus Iris, Inc. IRAK inhibitors and uses thereof
US9085586B2 (en) 2012-07-11 2015-07-21 Nimbus Iris, Inc. IRAK inhibitors and uses thereof
JP2016505012A (ja) 2013-01-10 2016-02-18 ニンバス アイリス， インコーポレイテッド Ｉｒａｋ阻害剤およびその使用
KR102153040B1 (ko) 2013-11-28 2020-09-07 삼성전자주식회사 축합환 화합물 및 이를 포함한 유기 발광 소자
GB201401886D0 (en) 2014-02-04 2014-03-19 Lytix Biopharma As Neurodegenerative therapies
CA3008171A1 (en) 2015-12-22 2017-06-29 SHY Therapeutics LLC Compounds for the treatment of cancer and inflammatory disease
BR112019027640A2 (pt) 2017-06-21 2020-07-07 SHY Therapeutics LLC composto, método para testar a capacidade de um ou mais compostos, método para inibir a função de ras, método para inibir a função de rho, método para inibir a função de rac, composição farmacêutica
WO2024035622A1 (en) * 2022-08-10 2024-02-15 Bellbrook Labs, Llc INHIBITORS OF cGAS ACTIVITY AS THERAPEUTIC AGENTS

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6232320B1 (en) * 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
EP1230225A2 (de) 1999-11-01 2002-08-14 Eli Lilly And Company Pharmazeutisch wirksame 4-substituierte pyrimidine derivate
US6608053B2 (en) * 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
WO2002062803A1 (fr) 2001-02-08 2002-08-15 Yamanouchi Pharmaceutical Co., Ltd. Derive de thienopyrimidine
AU2003237330A1 (en) 2002-06-06 2003-12-22 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted 3-amino-thieno[2,3-b]pyridine-2-carboxylic acid amide compounds and processes for preparing and their uses
CA2509758A1 (en) * 2002-12-17 2004-07-22 Schering Corporation 17 beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
PE20060526A1 (es) 2004-06-15 2006-07-13 Schering Corp Compuestos triciclicos como antagonistas de mglur1
US7598259B2 (en) 2004-06-15 2009-10-06 Schering Corporation mGluR1 antagonists as therapeutic agents
WO2006081072A1 (en) 2005-01-24 2006-08-03 Abbott Laboratories Antagonists of the mglu receptor and uses thereof

Also Published As

Publication number Publication date
CA2633093A1 (en) 2007-06-21
WO2007070393A2 (en) 2007-06-21
WO2007070393A3 (en) 2007-10-25
US7989464B2 (en) 2011-08-02
EP1966220B1 (de) 2011-01-26
US20090192178A1 (en) 2009-07-30
JP2009519337A (ja) 2009-05-14
DE602006019911D1 (de) 2011-03-10
CN101437828A (zh) 2009-05-20
US7598259B2 (en) 2009-10-06
US20060167029A1 (en) 2006-07-27
EP1966220A2 (de) 2008-09-10

Similar Documents

Publication Publication Date Title
TW200609231A (en) Mglur1 antagonists as therapeutic agents
ATE496922T1 (de) Mglur1-antagonisten als therapeutische wirkstoffe
WO2007038209A3 (en) Fused tetracyclic mglur1 antagonists as therapeutic agents
TW200738733A (en) Fused tricyclic mGluR1 antagonists as therapeutic agents
MA31117B1 (fr) Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoïdes
MA32898B1 (fr) Modulateurs allosteriques positifs du recepteur m1 d'arylmethylbenzoquinazolinone
TW200740826A (en) Fused tricyclic mGluR1 antagonists as therapeutic agents
UY28817A1 (es) Compuestos de imidazol para el tratamiento de trastornos neurodegerativos
ATE402935T1 (de) Kondensierte heterocyclische verbindungen und deren verwendung als antagonisten des metabotropen rezeptors zur behandlung von gastrointestinalen erkrankungen
MA28935B1 (fr) Preparation et utilisation de derives de biphenyl-4-yl-carbonylamino-acide dans le traitement de l'obesite
EA200702044A1 (ru) Имидазопиридазиновые соединения
EA200800100A1 (ru) Соединения азаиндазола и способы применения
EA200801934A1 (ru) 1,4-двузамещённые 3-циано-пиридоновые производные и их применение в качестве позитивных модуляторов рецепторов mglur2
ECSP055719A (es) Compuestos de tiazol para el tratamiento de trastornos neurodegenerativos
EA200802054A1 (ru) Ингибиторы фермента
ATE345329T1 (de) Pyridinderivate als modulatoren des cb2-rezeptors
EP1817312A4 (de) Makrozyklische aminiopyridyl-beta-sekretase-hemmer zur behandlung von morbus alzheimer
ATE517861T1 (de) Benzylether und benzylaminoverbindungen als inhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
EA200802020A1 (ru) Тетрагидропиримидоазепины и их применение в качестве модуляторов trpv 1
MA31567B1 (fr) Derives de 7 -alkynyl-1.8-naphthyrid0nes, leur preparation et leur application en therapeutique
EA200501595A1 (ru) Азабициклические производные в качестве антагонистов мускаринового рецептора
ATE466853T1 (de) Cgrp-rezeptorantagonisten
ATE407119T1 (de) Pyridinderivate und deren verwendung als modulatoren des cb2-rezeptors
PA8653901A1 (es) PIRAZOLO (3,4-b) PIRIDINAS E INDAZOLES TERAPEUTICOS
ATE523199T1 (de) Pyridazinverbindungen und verfahren

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties